- Home
- CHRS vs CMCM Comparison
CHRS vs CMCM Comparison
Compare CHRS & CMCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- CMCM
- Stock Information
- Founded
- CHRS 2010
- CMCM 2009
- Country
- CHRS United States
- CMCM China
- Employees
- CHRS N/A
- CMCM N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- CMCM Computer Software: Prepackaged Software
- Sector
- CHRS Health Care
- CMCM Technology
- Exchange
- CHRS Nasdaq
- CMCM Nasdaq
- Market Cap
- CHRS 186.0M
- CMCM 195.2M
- IPO Year
- CHRS 2014
- CMCM 2014
- Fundamental
- Price
- CHRS $1.11
- CMCM $6.60
- Analyst Decision
- CHRS Strong Buy
- CMCM
- Analyst Count
- CHRS 4
- CMCM 0
- Target Price
- CHRS $4.51
- CMCM N/A
- AVG Volume (30 Days)
- CHRS 1.4M
- CMCM 25.2K
- Earning Date
- CHRS 11-06-2025
- CMCM 11-26-2025
- Dividend Yield
- CHRS N/A
- CMCM N/A
- EPS Growth
- CHRS N/A
- CMCM N/A
- EPS
- CHRS 1.34
- CMCM N/A
- Revenue
- CHRS $277,728,000.00
- CMCM $137,272,956.00
- Revenue This Year
- CHRS N/A
- CMCM $14.27
- Revenue Next Year
- CHRS $109.48
- CMCM $39.26
- P/E Ratio
- CHRS $0.82
- CMCM N/A
- Revenue Growth
- CHRS 152.07
- CMCM 38.54
- 52 Week Low
- CHRS $0.71
- CMCM $3.28
- 52 Week High
- CHRS $2.43
- CMCM $9.44
- Technical
- Relative Strength Index (RSI)
- CHRS 31.08
- CMCM 35.70
- Support Level
- CHRS $1.09
- CMCM $6.21
- Resistance Level
- CHRS $1.25
- CMCM $7.41
- Average True Range (ATR)
- CHRS 0.13
- CMCM 0.33
- MACD
- CHRS -0.04
- CMCM -0.10
- Stochastic Oscillator
- CHRS 0.81
- CMCM 12.89
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
About CMCM Cheetah Mobile Inc. each representing fifty (50)
Cheetah Mobile Inc along with its subsidiaries provides comprehensive products and services on PCs and mobile devices. It generates revenue from utility-related business, including advertising services and premium membership services. It also provides multi-cloud management platform and overseas advertising agency service. The company operates in two segments: Internet business, and AI and others. The firm's majority of the revenue is derived from the internet business segment that provides mobile advertising services to advertising customers, as well as selling advertisements and referring user traffic on its mobile and PC platforms. Geographically, it derives the majority of its revenue from the PRC and the rest from Hong Kong, Japan, and the rest of the world.